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Abstract
Recently, a remarkable increase in the incidence of zygomycosis has been reported from institutions in the USA and Europe. The use
of voriconazole for the treatment of aspergillosis and, less frequently, the use of echinocandins as empirical treatment for invasive fungal
infections are thought to be responsible for the increase. In addition, an increased incidence of this infection has been observed in
transplant recipients, including both haematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT) patients. There are
no global surveys on the prevalence or incidence of zygomycosis, but data from individual institutions and countries show that zygomy-
cosis is an emerging infection. The increased incidence of zygomycosis most probably reﬂects a greater frequency of predisposing fac-
tors, such as higher numbers of patients undergoing HSCT and immunosuppressive chemotherapy. In addition, the emergence of rare
pathogens as a result of the rise in the use of antifungal therapy against common species can be postulated. Further, the availability of
antifungal agents with activity proﬁles that are more speciﬁc for selected fungi increases the necessity of identifying pathogenic fungi; the
frequency of Zygomycetes infections may have been underestimated until now because therapeutic decisions did not depend on the
precise identiﬁcation of pathogenic fungi.
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Introduction
The Zygomycetes are ubiquitous and thermo-tolerant micro-
organisms which are largely saprotrophic, feeding on decay-
ing organic matter, including vegetables, fruits, seeds, bread,
soil, compost piles and animal excreta. These species sporu-
late abundantly and spores are easily airborne [1].
In general, members of the Mucorales cause the more
severe form of zygomycosis, also called mucormycosis,
whereas the Entomophthorales cause more chronic disease
of the nasal mucose and subcutaneous tissue. These infec-
tions are uncommon in immunocompetent patients, in whom
they cause a localized infection that is easily treatable. How-
ever, mucormycosis in the debilitated patient may be the
most fulminate opportunistic fungal infection known [2,3].
Mycoses caused by the Mucorales are emerging fungal
infections which occur in immunocompromised patients.
Recently, a remarkable increase in their incidence has been
reported from single institutions in the USA and Europe
[4,5]. The use of voriconazole for the treatment of aspergil-
losis and, less frequently, the use of echinocandins as empiri-
cal treatment for invasive fungal infections (IFI) are thought
to be responsible for the increased incidence of zygomycosis
[2,6,7].
An increased incidence of these fungal infections has also
been observed in transplant recipients, including both hae-
matopoietic stem cell transplant (HSCT) and solid organ
transplant (SOT) patients. There are no global surveys of the
incidence of zygomycosis, but data from individual institu-
tions and countries show that zygomycosis seems to be a
new and emerging concern in these groups of patients [2].
We reviewed reports and publications on the incidence of
zygomycosis in transplant recipients and determined if the
increase in its incidence can be considered signiﬁcant from
an epidemiological point of view. We undertook a MEDLINE
search using the keywords ‘zygomycosis’, ‘mucormycosis’,
‘Rhizopus’, ‘Mucor’, ‘Rhizomucor’, ‘Absidia’, ‘Cunninghamella’,
‘transplant recipients’, ‘solid organ transplantation’ and ‘hae-
matopoietic stem cell transplantation’, as well as a text word
search. We included reports published on MEDLINE from
1970 onward. The analysis was divided into two periods to
include reports published during 1970–2005 and those
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published during 2006–2008. We separated the reports
according to these time periods because surveys showing an
increase in the incidence of zygomycosis supposedly caused
by the use of voriconazole were initially reported in 2005
and, if voriconazole represents a risk factor for outbreaks of
zygomycosis, an increased incidence in reports should be
observed from that year onward.
Analysis of Reports of Zygomycosis in
Transplant Recipients During 1970–2005
As stated above, there are no global surveys of the preva-
lence of incidence of zygomycosis. Most published data con-
sist of reports from single institutions and retrospective
studies depicting the epidemiological status of zygomycosis in
single countries. There are also a limited number of publica-
tions on multicentre prospective studies analyzing the inci-
dence of zygomycosis in both SOT and HSTC recipients.
One of those prospective surveys was performed by RESI-
TRA (Spanish Net for Research in Transplant Recipients), a
research network formed by 16 transplant centres and three
reference laboratories, which prospectively analyzed all SOT
and HSCT recipients from 2003 to 2005. A total of 3487
patients were included (2615 SOT and 872 HSCT patients).
The rate of IFI was 3.8% (133 cases). Only two cases of
zygomycosis were described (2/133, 1.5%) and both
occurred in allograft HSCT recipients.
Data from the USA can be accessed in the multicentre
register TRANSNET, which has recorded infections in trans-
plant patients since 2001. In 2003 the published rate of zygo-
mycosis in liver and heart transplant recipients suffering from
IFI in some American institutions was 5.7% [8]. Other Amer-
ican institutions have reported prevalences of zygomycosis in
SOT and HSCT in the range of 0.2–3.5% [9–14].
Authors from other countries have published surveys with
fragmentary data on the prevalence of zygomycosis in their
institutions. Studies from Austria, Belgium, Italy and France
have revealed infection rates in the range of 0.3–2.0% [15–
19]. Non-European countries such as Japan, Brazil, Israel and
Kuwait have reported similar ﬁgures of zygomycosis preva-
lence [20–23], but India and Iran have reported higher rates,
particularly in kidney transplant recipients [24,25], and an Ira-
nian centre reported a prevalence as high as 7.8% (4/51
cases) in orthotopic liver transplant recipients [26].
In addition, there are two exhaustive literature reviews on
zygomycosis in transplantation which include cases reported
up to 2005 [27,28]. These reviews report a total of 160
cases of zygomycosis in transplant recipients. Notably, 108
cases (65%) refer to SOT patients, of whom 73 underwent
renal transplants, 19 underwent liver transplants and 16
underwent heart transplants. The most frequent clinical pre-
sentation was pulmonary infection, which occurred in 26% of
transplant recipients with zygomycosis. Table 1 displays the
most common presentations of zygomycosis in these groups
of patients.
Analysis of Reports of Zygomycosis in
Transplant Recipients During 2006–2008
Some anecdotal case reports published in 2004 and surveys
published in 2005 indicate that an increased incidence of
zygomycosis may be occurring as a result of the use of voric-
onazole to treat aspergillosis and other fungal infections
[2,4–7,29–31]. This rise has been observed particularly in
patients suffering from malignancies or in those who have
undergone HSCT [4].
In the last 3 years, a signiﬁcant increase in the incidence
of breakthrough zygomycosis has been observed. This
increase has occurred mainly in allo-HSCT patients on anti-
fungal prophylaxis, but there have also been some reports of
an increased incidence of zygomycosis in SOT [7,11,32–36].
In 2007 Triﬁlio et al. [37] published a cohort study on
zygomycosis after voriconazole exposure in 13 oncological
centres in the USA. Patients were enrolled after ‡5 days of
voriconazole therapy and were diagnosed by culture or his-
tology. A total of 58 cases were detected, of whom 56
(96.5%) had been treated with voriconazole. Among trans-
plant recipients, a total of 36 of 58 cases (62%) referred to
patients who had undergone HSCT [37].
Spanish institutions within RESITRA have detected ten
cases of zygomycosis (data not published), of which seven
occurred in HSCT and three in SOT patients. In addition,
some Spanish institutions have reported an incidence of 0.62
cases per 100 000 hospital admissions [38].
Including surveys and case reports, the literature reports
a total of approximately 200 cases of zygomycosis in trans-
plant recipients, of which 160 occurred up to 2005 and 40
TABLE 1. Most common clinical presentations of zygo-
mycosis in transplant recipients according to Davari et al.
(2003) [26] and Almyroudis et al. (2006) [27]
Clinical presentation
Percentage (%) of
zygomycosis cases
Pulmonary 26
Rhino-sino-orbital 20
Cutaneous 17
Rhinocerebral 15
Disseminated 12
Gastrointestinal 10
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occurred during the subsequent 3 years [4,5,7,11,19,28,
32–37].
Discussion
At present, Candida and Aspergillus spp. are the most common
causes of opportunistic fungal infection, but other rare
emerging species belonging to several groups, such as the
Zygomycetes, are increasingly reported as causes of lethal
infection. Several factors have been proposed as causes of
the increasing numbers of reports of opportunistic infections
and the emergence of rare moulds. Environmental changes,
antimicrobial pressure and an expanding population of immu-
nocompromised hosts are the most commonly proposed. In
addition, efﬁcient control and eradication of more prevalent
species can extend the niche of rare and more resistant fungi
[3]. The use of voriconazole for the treatment of aspergillosis
may be responsible for the increase in the incidence of zygo-
mycosis because it is inactive against Zygomycetes [6, 37].
It could also be argued that the increase in the number of
cases reported may not be as signiﬁcant as it appears and
that the incidence of zygomycosis has been underestimated
for two reasons. Firstly, until recently there has been a
shortage in the number of medical mycology experts with
the capability to identify rare fungi. Secondly, there has been
a lack of interest in the precise identiﬁcation of pathogens as
distinct alternatives for treatment were not available; thus,
although it was essential to know if the patient was suffering
from a fungal infection, it was not vital to identify the genus
and species. Consequently, for many years there has been a
lack of reliable epidemiological information with which to
ascertain the prevalence and incidence of fungal infections
that have been precisely identiﬁed.
Conclusions
We consider that there may be a combination of explana-
tions for the increased incidence of reports of zygomycosis.
The signiﬁcant rise reﬂects a greater frequency of predispos-
ing factors, such as higher numbers of patients undergoing
HSCT and immunosuppressant chemotherapy. In addition,
the emergence of rare pathogens as a result of the increased
use of antifungal therapy against common species is plausible.
However, it should also be accepted that the current avail-
ability of several antifungal agents with activity proﬁles that
are more speciﬁc for selected fungal species increases the
interest of identifying fungal species and that the prevalence
of Zygomycetes may have been underestimated until now.
It should also be noted that emergent fungal infections will
continue to increase in clinical settings in which experts such
as microbiologists, haematologists and paediatricians are
interested in precise fungal identiﬁcation.
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